Circulation, Vol 65, 348-354, Copyright © 1982 by American Heart Association
S Gulamhusein, P Ko, SG Carruthers and GJ Klein
We examined the electrophysiologic effects of verapamil in eight patients
with the Wolff-Parkinson-White syndrome. Verapamil shortened the antegrade
effective refractory period of the accessory pathway in three patients and
abbreviated the shortest cycle length with 1:1 conduction over the
accessory pathway in two patients. More significantly, verapamil decreased
the shortest RR interval between preexcited ventricular complexes during
atrial fibrillation (279 +/- 20 msec vs 236 +/- 18 msec, mean +/- SEM; p
less than 0.01). After verapamil, two patients required cardioversion for
hemodynamic deterioration after acceleration of the ventricular response
during atrial fibrillation. In the four patients with predominantly
preexcited ventricular complexes during atrial fibrillation the ventricular
rate accelerated after verapamil, whereas in patients with predominantly
normal ventricular complexes, the average ventricular rate decreased or did
not change after verapamil. Verapamil may result in significant
acceleration of ventricular response during atrial fibrillation in the
Wolff-Parkinson-White syndrome. The safety of verapamil in individual
patients with the Wolff-Parkinson-White syndrome should be established by
electrophysiologic testing before its use.
ARTICLES
Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil
This article has been cited by other articles:
![]() |
L. I. Ganz and P. L. Friedman Supraventricular Tachycardia N. Engl. J. Med., January 19, 1995; 332(3): 162 - 173. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1982 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |